Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
elubrixin
- Development stage
- Phase 2
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Elubrixin (SB-656933) is a potent, selective, competitive, reversible, and orally active small molecule antagonist of the C-X-C chemokine receptor type 2 (CXCR2, also known as interleukin 8B receptor). It inhibits neutrophil activation and recruitment by blocking IL‑8–mediated signaling pathways. Elubrixin was developed by GlaxoSmithKline for inflammatory diseases such as chronic obstructive pulmonary disease (COPD), cystic fibrosis, and ulcerative colitis. The drug reached Phase II clinical trials but development was discontinued due to lack of efficacy[1][2][3][4][5].
- Brand names
- Elubrixin
- Other names
- elubrixin tosylateelubrixin free base
02
Targets
CXCR2 (C-X-C Motif Chemokine Receptor 2)
Beyond the preview
Go deeper on elubrixin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on elubrixin.